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Current vaccine conditions predominantly elicit
low-avidity cytotoxic T lymphocytes (CTLs), which
are non-tumor-cytolytic but indistinguishable by
tetramer staining or enzyme-linked immunospot
from high-avidity CTLs. Using CTL clones of high
or low avidity for melanoma antigens, we show
that low-avidity CTLs can inhibit tumor lysis by
high-avidity CTLs in an antigen-specific manner.
This phenomenon operates in vivo: high-avidity
CTLs control tumor growth in animals but not in
combination with low-avidity CTLs specific for the
same antigen. The mechanism involves stripping
of specific peptide-major histocompatibility com-
plexes (pMHCs) via trogocytosis by low-avidity
melanoma-specific CTLs without degranulation,
leading to insufficient levels of specific pMHC on
target cell surface to trigger lysis by high-avidity
CTLs. As such, peptide repertoire on the cell sur-
face is dynamic and continually shaped by interac-
tions with T cells. These results describe immune
regulation by low-avidity T cells and have implica-
tions for vaccine design.
INTRODUCTION
Cancer vaccines have been shown to elicit detectable cyto-
toxic T lymphocyte (CTL) responses in patients, but such re-
sponses have not correlated with clinical outcome (Lollini
et al., 2006). We previously demonstrated that vaccine-elicited
T cells are heterogeneous with respect to tumor-killing capacityand only a small subset of vaccine-elicited T cells are efficient
at tumor cell lysis (Stuge et al., 2004). This is largely due to dif-
ferences in functional avidity (also known as recognition effi-
ciency): peptide-specific T cells indistinguishable by tetramer
staining may differ by up to 1,000-fold in peptide requirement
for target lysis. Only high-avidity CTLs, which may represent
10% or less of a vaccine-elicited response, could lyse tumor
targets (Stuge et al., 2004). Low-avidity T cells, which are
non-tumor-cytolytic, represent the predominant cell population
elicited via vaccine conditions that involve high, supraphysio-
logical antigen doses. Under these conditions, it remains un-
clear whether low-avidity CTLs are simply inert or may actively
compete against or interfere with high-avidity T cells in tumor
lysis.
Prior studies have shown that the competition between anti-
gen-specific T cells for interaction with cognate peptide- major
histocompatibility complexes (MHCs) plays an important role in
determining the levels of immune responses, such as epitope
dominance and affinity maturation in secondary T cell re-
sponses (Butz and Bevan, 1998; Kedl et al., 2000, 2002). In
these studies, competition occurs at low antigen levels or
when there is limited accessibility to surface molecules associ-
ated with immunological synapses (i.e., MHC or costimulatory
molecules) on antigen-presenting cells (APCs) during the induc-
tion phase (Kedl et al., 2000). In this report, we demonstrate
that, even after being elicited, antitumor activity of high-avidity
CTL can still be inhibited by low-avidity CTL in an antigen-spe-
cific manner in vitro and in vivo. This inhibition occurs through
a trogocytosis mechanism in which low-avidity CTLs strip
cognate peptide-MHCs from the target cell surface without
killing, leaving subthreshold levels of target peptides accessible
to high-avidity CTLs. Antigen-specific inhibition of high-avidity
CTLs by low-avidity CTLs represents a mechanism of immune
regulation.Cell Reports 8, 871–882, August 7, 2014 ª2014 The Authors 871
Figure 1. TAA-Specific Low-Avidity CTL Can Inhibit Lysis of Melanoma Cells by High-Avidity CTL
(A and B) Gp100-specific CTL clones.
(C and D) MART-specific CTL clones.
(A and C) High- and low-avidity CTL clones vary greatly in efficiency at tumor cell lysis; (B and D) high-avidity CTL lysis of tumor cells can be inhibited by pre-
incubation of tumor cells with nontumor lytic low-avidity CTL. For each assay in (B) and (D), 104 51-chromium(Cr)-labeled mel526melanoma cells were combined
with 53 104 to 83 105 low-avidity TAA-specific or virus-antigen-specific CTL by centrifugation at 2003 g and incubated 1.5 hr before addition of 105 high-avidity
TAA-specific CTL to a final volume of 200 ml. This was followed by additional 1.5 hr incubation. For assays in (A) and (C), low-avidity cells were substituted with an
equivalent volume culture medium. Forty microliters cell-free supernatant was harvested and percent specific release (PSR) of 51-chromium calculated.
Calculation of percent specific release was described previously (Rubio et al., 2003). Percent inhibition was calculated by the formula 1003 (PSR[high avidity +
mel526]  PSR[high + low avidity + mel526])/PSR(high avidity + mel526). Bars reflect SD between assays in three separate experiments.
(E) Changes in expression of apoptotic markers 7AAD and annexin V on mel526 target cells at 4 and 24 hr. Bar graph illustrates the percent change in apoptotic
markers for each group (4 hr time point: high versus low, p% 0.01; high versus low + high, p% 0.016) and (24 hr time point: high versus low, p% 0.01; high versus
low + high, p% 0.01). Assays were performed in triplicate.RESULTS
Low-Avidity CTLs Inhibit High-Avidity-CTL-Mediated
Tumor Cell Lysis
We assessed tumor cell lysis by high-avidity tumor-associated
antigen (TAA)-specific CTL in the presence or absence of low-872 Cell Reports 8, 871–882, August 7, 2014 ª2014 The Authorsavidity TAA-specific CTL or virus-specific CTL as specificity
controls. Mel526 cells were preincubated with one of three
different low-avidity human leukocyte antigen – type A locus
(HLA-A)*02:01-restricted CTL clones specific for the gp100
(209–217) peptide (G209n: ITDQVPFSV) prior to addition of
G209n-specific, high-avidity CTL clones (Figures 1A and 1B).
Table 1. Characterization of MART-1- and gp100-Specific CTL
Clones by Functional Avidity
TAA
Specificity Clone
Avidity for
Native Peptidea
Functional
Avidityb
Gp100 476.139 11.2 high
422.50 10.4 intermediate
422.47 10.0 low (no. 1)
476.105 8.3 low (no. 2)
MART-1 461.9 8.2 high
461.24 7.7 high
520.31 5.1 low
517.7 5.1 low
461.10 6.1 low
517.2 6.4 intermediate
517.3 4.8 low
520.33 6.3 intermediate
aAvidity for native peptide was determined as peptide concentration
resulting in 40% lysis (50% of maximum) of peptide-pulsed T2 cells.
The generally higher values of gp100 in comparison to MART avidity
scores is likely due to differences in peptide-MHC half-life between the
two peptides.
bFunctional avidity was determined by efficiency at melanoma cell lysis.
Low, <10% lysis; Intermediate,R10%–40% lysis; High, >40% lysis.These clones, all isolated from cancer patients, were character-
ized for efficiency in lysis of mel526 cells and for avidity based on
peptide titrations (Table 1). High- and low-CTL-avidity clones
were equivalent in lysis of T2 cells pulsed with high levels
(1 mg/ml) of cognate peptide and hence were all fully competent
to kill. Peptide titration curves for a high-avidity versus a low-
avidity clone are shown in Figure S1, demonstrating a 1,000-
fold difference in peptide responses between these clones that
are specific for the same G209 peptide. High- and low-avidity
CTLs differed significantly in their abilities to lyse melanoma
targets (Figures 1A and 1C). Whereas the high-avidity clone
476.139 efficiently lysedmel526 cells in the absence of low-avid-
ity cells (Figure 1A), lysis was inhibited following preincubation of
the mel526 target cells with each of the low-avidity clones (Fig-
ure 1B). This inhibition was not merely due to steric hindrance
because preincubation of mel526 cells with a CTL clone specific
for influenza peptide (FLU: GILGFVFTL) resulted in little or no
inhibition (Figure 1B). Similar inhibition was seen when assaying
for inhibition of mel526 cell lysis by high-avidity clones specific
for the MART (27–35) peptide (M27: ELAGIGILTV) by preincuba-
tion of mel526 cells with two low-avidity M27-specific clones,
but not with a clone specific for cytomegalovirus (CMV) peptide
(NLVPMVATV; Figures 1C and 1D). We further confirmed
whether target cell death induced by high-avidity CTLs is in-
hibited by the presence of low-avidity CTLs via a flow-based
apoptosis assay. We found the same inhibitory results in the
presence of low-avidity CTLs using mel526 target cells. The
overall percentage of mel526 cells that were positive for both
7-aminoactinomycin D (7AAD) and annexin V was significantly
less in the presence of low-avidity CTLs at 4 and 24 hr time points
(Figure 1E; 4 hr time point: high versus low, p% 0.01; high versus
low + high, p % 0.016; 24 hr time point: high versus low, p %0.01. high versus low + high, p% 0.01). Inhibition by low-avidity
CTL clones of target lysis was also found with MeWo cells, and
additionally, the optimal inhibition time was determined to be
after 1 hr preincubation of melanoma cells with low-avidity CTL
(Figure S2). Thus, the presence of low-avidity CTL clones inhibits
lysis of melanoma cells by high-avidity CTL.
High-Avidity CTL Lysis of Tumor Cells In Vitro, and
Control of Tumor Growth In Vivo Is Inhibited by
Low-Avidity CTLs in an Antigen-Specific Manner
To determine if this inhibitory effect is antigen specific, mel526
cells were incubated with low- and high-avidity CTL clones
specific for G209n, MART, or viral peptides in various combina-
tions (Figures 2A and 2B). Maximal inhibition was detected only
when low- and high-avidity clones of the same peptide specificity
were combined with melanoma targets. Whereas high-avidity
G209n-specific CTLs were significantly inhibited by low-avidity
G209n-specific CTLs, low-avidity MART-specific CTLs had little
to no inhibition, similar to that of viral antigen-specific CTLs
(Figure 2A). An identical pattern was seen with high-avidity
MART-specific CTLs and low-avidity MART-specific CTLs, but
not G209n-specific CTLs (Figure 2B). Inhibition was antigen-spe-
cific because high-avidity and low-avidity CTLs specific for two
different antigens (MART or G209n) did not significantly cross-
inhibit. This pattern was confirmed using a number of different
low-avidityG209n-specificandMART-specificclones (FigureS3).
The antigen-specific nature of inhibition suggests that low-avidity
CTLs prevent high-avidity CTLs from recognizing or responding
to specific peptide-MHCs on the surface of target cells.
To examine whether inhibition of high-avidity CTL lysis of
tumor cells by low-avidity CTL could occur in vivo, we injected
severe combined immunodeficiency (SCID) micewithmelanoma
cells subcutaneously followed by intravenous injections of
various combinations of high-avidity CTLs with low-avidity or
virus-specific CTLs. Tumor size was monitored to 40 days after
CTL injections. In mice injected with a combination of high-avid-
ity and low-avidity G209n-specific CTLs, tumor growth was
significantly higher than in mice injected with high-avidity
G209n-specific CTLs alone (p < 0.01) or high-avidity G209n-spe-
cific CTLs together with FLU-specific CTLs (p = 0.02; Figure 2C).
These results demonstrate that this antigen-specific CTL inhibi-
tion can also take place in vivo.
Tetramer Decay Reveals Low-Avidity CTLs Have Lower
Relative TCR Affinity for Native Peptide in Comparison
to High-Avidity CTLs
T cell avidity is driven primarily by T cell receptor (TCR) affinity for
its cognate peptide (Corse et al., 2011; Denton et al., 2011; Gour-
ley et al., 2004) and also expression levels of CD3/TCR complex
and adhesion molecules. We determined that high- and low-
avidity clones expressed CD3/TCR at similar levels (data not
shown). To assess relative TCR affinities of the high- and low-
avidity CTLs, we utilized the tetramer decay assay, which has
been validated to determine the relative TCR affinity of intact
T cells (Savage et al., 1999; Turner et al., 2008; Wang and Alt-
man, 2003). Low-avidity G209-specific CTL clone showed signif-
icantly more rapid tetramer decay kinetics (p < 0.01) than
the high-avidity clone. Results plotted show the reduction inCell Reports 8, 871–882, August 7, 2014 ª2014 The Authors 873
Figure 2. High-Avidity CTL Lysis of Tumor Cells In Vitro and Suppression of Tumor Growth In Vivo Is Inhibited by Low-Avidity CTLs in an
Antigen-Specific Manner
Assays were performed as described in legend for Figure 1.
(A and B) Gp100-specific (A) or MART-specific (B) high-avidity CTL were combined with Gp100-specific or MART-specific low-avidity CTL or FLU-specific CTL.
Percent inhibition of melanoma cell lysis was calculated as in legend for Figure 1. Bars represent SD between three separate assays, each performed in triplicate.
(C) Suppression of tumor growth in vivo by high-avidity CTLs was inhibited by low-avidity CTLs, but not by a CTL clone of irrelevant specificity (flu-peptide-
specific CTL). C57BL SCID (common gamma/RAG2 double-knockout) mice were injected subcutaneously with mel526 human tumor cells. Results indicate
tumor size 40 days postinjection of G209n-specific high-avidity CTL (tu hi), G209n-specific high-avidity CTL combined with G209n-specific low-avidity CTL (tu
hi lo), or G209n-specific high-avidity CTL combined with flu-specific CTL (tu hi flu).
(D) Reduction of MFI of iTag G209-specific MHC class I human tetramer-streptavidin (SA)-PE (normalized to initial MFI at 0 min) from CD8-labeled low- (B) and
high (,)-avidity G209-specific CTL clones were plotted versus time elapsed postincubation with blocking HLA-A2 Fab fragment. Also provided are control plots
of low- (D) and high (>)-avidity CTL clones that are tetramer/CD8 stained and collected at same time points without addition of HLA-A2 Fab fragment. Results are
representative of three separate experiments. Data were fitted using a linear mixed effects model to test intercept and slope over time by group effects.
Calculations were based on the nlme package in R version 2.12.1.tetramer mean fluorescent intensity (MFI), normalized to initial
MFI at 0 min, which represents the tetramer decay in low-avidity
CTLs (B) and high-avidity CTLs (,) over time (Figure 2D). These
results strongly support that TCR affinity for the native peptide is
higher for the high-avidity clone than the low-avidity clone.
Visualizing CTL Cross-Inhibition in 3D Culture System
To model and study the in vivo situation, we generated a 3D
culture system to replicate in vivo tumor-T cell interactions.874 Cell Reports 8, 871–882, August 7, 2014 ª2014 The AuthorsCell aggregates were formed by centrifugation of G209n-spe-
cific CTLs with mel526 cells and culturing these aggregates on
nucleopore filters (Figure 3A). Based on immunohistochemical
analyses, mel526 aggregates mixed with either low-avidity
CTLs only or the combination of both high and low CTLs led
to much lower numbers of mel526 cells expressing apoptotic
marker caspase 3 as compared to aggregates containing
mel526 and only high-avidity CTLs (Figure 3B). As shown in Fig-
ure 3C, counts of viable (nonlysed) mel526 cells in a fixed
Figure 3. Visualizing CTL Cross-Inhibition in a 3D Culture System
(A) Schematic of generating mel526/CTL aggregates for in vitro models. Cultured mel526 cells (2 3 105 cells) plus either high- (1 3 105) or low (1 3 105)-avidity
CTLs or combination of high- and low-avidity CTLs cells were mixed to form aggregates. Aggregates were then cultured on nucleopore membranes floating in
Dulbecco’s modified Eagle’s medium supplemented with 10% FBS for 48 hr for in vitro analyses.
(B) Paraffin-embedded aggregate tissue sections from each group were analyzed for expression of melanin A (brown), hematoxylin (blue), and caspase 3 (red).
Shown are representative sections. See Quantification of Viable Mel526 Cells in Tumor/CTL Aggregate for image acquisition information.
(C) Bar graph representing the viable cell count of tumor aggregates. Counts were determined from the paraffin embedded sections of each aggregate imaged at
203. Mean cell counts for six independent areas of each aggregate are reported. Unpaired t test of the data groups was performed, and statistical significance
was given for p < 0.05.dimension area for each slide were identified by utilizing Image
Pro Premier automated cell counting for each tumor/CTL aggre-
gate combination. The results indicate a statistically significant
reduction in the number of viable mel526 cells in the presence
of high-avidity CTLs only as compared to low-avidity CTLs (p <
0.0001) or the combination of both low- and high-avidity CTLs
(p < 0.0001). In addition, similar results were also observed
when mel526 3D spheroids were challenged with the different
combination of high- and low-avidity CTLs (Figure S4). Because
tumor spheroids resemble many similar aspects of tumor micro-
environments, they are commonly utilized to study the efficacy of
antitumor treatments (Zhang et al., 2005). When the emission of
fluorescence signals from calcein-labeled mel526 cell spheroids
in the presence of G209n-specific CTLs were evaluated, wedetected the significantly reduced levels of fluorescence in the
presence of high-avidity CTLs compared to low or high plus
low-avidity CTLs. These analyses demonstrate that, in addition
to the higher tumor-specific lytic capacity of the high-avidity
CTLs in comparison to low-avidity CTLs against mel526, low-
avidity CTLs can inhibit tumor lysis by high-avidity CTLs in the
3D tumor spheroid and aggregate coculture models. Error bars
represent SD between assays (high versus low: p % 0.01; high
versus low + high: p% 0.01).
Low-Avidity CTLs Strip Specific Peptide-MHCs from the
Surface of Target Cells
We hypothesized that interaction of low-avidity CTLs with target
cells may lead to modulation of the target cell’s surface antigensCell Reports 8, 871–882, August 7, 2014 ª2014 The Authors 875
Figure 4. Low-Avidity CTLs Reduce Specific Peptide-MHCs on the Surface of Tumor Cells
(A) Changes in biotin-tagged cognate peptide levels analyzed for stripping from the surface of target cells by low-avidity CTL. Remaining cognate peptide
concentration analyzed by flow cytometry for SA-PE fluorescence intensity. Bars reflect SD between assays in three separate experiments.
(B) To visualize trogocytosis, immortalized B cells expressing HLA-A*02:01 coupled to GFP (HmyA2GFP cells) were pulsed with G209n-specific peptide and
incubated with G209n-specific low-avidity CTLs. Formation of clusters between CTLs and HmyA2GFP cells were visualized via live-cell fluorescent microscopy
at 5 min (left panel). Small membrane fragments of HLA-GFP expression on the surface of CD8+ T cells appeared after 15–30 min (right panel).
(C) An increase in intracellular calcium concentration is directly associated with both high- and low-avidity CTLs undergoing trogocytosis. HmyA2GFP cells were
pulsed with G209n peptide (1 ng/ml) and incubated with either G209n high- or low-avidity CTLs for 7 min. Following incubation, GFP+CD8+ cells were gated and
compared to GFPCD8+ cells for the levels of intracellular calcium concentration.without cytolysis. To test this hypothesis, target cells were incu-
bated with G209n peptides containing a biotinylated linker pep-
tide. Biotin/peptide-pulsed target cells were then incubated with
low-avidity G209n-specific or viral antigen-specific CTL clones
and then reacted with streptavidin-phycoerythrin (PE) and
analyzed by flow cytometry to determine the potential downmo-
dulation of specific peptide-MHCs on the surface of target cells
following interaction with CTL. Indeed, target cells incubated
with low-avidity G209n-specific CTL clones bound less strepta-
vidin-PE compared to target cells treated with FLU-specific CTL
or no CTL, suggesting that the target cell surface density of
G209n peptide-MHCs had been reduced by interaction with
low-avidity G209n-specific CTLs (Figure 4A).876 Cell Reports 8, 871–882, August 7, 2014 ª2014 The AuthorsWe reasoned that a potential mechanism of inhibition could be
stripping of specific peptide-MHCs on the target cell surface by
low-avidity TAA-specific T cells via trogocytosis or other forms of
sequestration (Hudrisier et al., 2005; Tomaru et al., 2003; Uzana
et al., 2012). To test this hypothesis, we used immortalized B
cells expressingHLA-A*02:01 coupled toGFP (HmyA2GFP cells)
pulsed with G209n peptide and incubated them with G209n-
specific low-avidity CTLs (Tomaru et al., 2003). Within 15 min,
formation of conjugates between CTLs and HmyA2GFP cells
were visualized and small membrane fragments of HLA-GFP
expression on the surface of CD8+ T cells appeared after
30 min (Figure 4B; Movie S1). Based on previous reports
indicating that the specificity of peptide-HLA-TCR recognition
initiates trogocytosis and that consistent TCR stimulation results
in elevated intracellular calcium concentration in T cells, we
examined the fluctuation of intracellular calcium levels in both
high- and low-avidity CTLs during trogocytosis (Joseph et al.,
2014; Osborne and Wetzel, 2012). As shown in Figure 4C, an
increase in intracellular calcium concentration is directly associ-
atedwith both high- and low-avidity CTLs undergoing trogocyto-
sis, indicating that TCR signaling precedes trogocytosis. We
next postulated that the level of trogocytosis is directly associ-
ated with the amount of peptides presented. Different concen-
trations of G209n peptide were pulsed onto HmyA2GFP cells
and incubated with either high- or low-avidity G209n-specific
CTLs. The percentage of GFP+ CTLs following incubation re-
vealed that the capacity for trogocytosis of both high- and low-
avidity G209n clones directly correlated to the amount of
G209n peptide concentration. Importantly, low-avidity CTLs dis-
played a similar trogocytosis capacity as compared with high-
avidity CTLs, further reflecting their ability to reduce specific
peptide-MHCs on the surface of target cells (Figure 5A).
We then examined whether or not tumor cells could induce
trogocytosis by G209n-specifc CTLs. To test this, we used
PKH67-labeled mel526 as the target. As shown in Figure 5B,
the level of fluorescence signals detected from both high- and
low-avidity G209n-specific CTLs was not significantly different
(12.6% from high versus 13.1% from low). This result fits within
the range of earlier G209-peptide-dependent trogocytosis in
Figure 5A (concentration of G209n peptide between 1 pg and
0.1 pg/ml). Taken together, these results show that low-avidity
CTL can strip peptide-MHCs from target cells via trogocytosis
even at peptide concentrations that are too low to induce target
cell killing by these cells.
Degranulation following Trogocytosis in High- versus
Low-Avidity CTL
Given that both high- and low-avidity G209n-specific CTL clones
displayed similar capacity for trogocytosis following interaction
with G209n peptide-pulsed HmyA2GFP cells, we wanted to
examine to what extent trogocytosis by low-avidity CTL can
reduce the cytolytic ability of high-avidity CTL. To accomplish
this, we measured mobilization of CD107 (LAMP-1), a surrogate
marker for lysosomal degranulation, on CTLs in relation to trogo-
cytosis (Rubio et al., 2003). HmyA2GFP cells were pulsed with
G209n peptides, incubated with either high- or low-avidity
CTLs, and analyzed for the expression of CD107 on GFP-posi-
tive CTLs (red boxes, Figure 6A). The level of GFP in both high-
and low-avidity CTLs was similar, suggesting that their ability
to trogocytose in a dose-dependent fashion is relatively similar.
The majority of high-avidity CTLs expressing CD107 were also
positive for GFP, supporting a strong correlation between trogo-
cytosis and degranulation activity. In contrast, we observed that
the percentage of CD107 from GFP-positive low-avidity CTLs
was significantly less than that of high-avidity CTL. Similar re-
sults were observed with PKH67-labeled mel526 cells as a
target; a considerably higher frequency of PKH67-positive
CTLs (red boxes, Figure 6B) was observed with high-avidity
CTLs (29.1%) compared to low-avidity CTLs (6.9%). Moreover,
the frequency of CD107 expression specifically in prestained
and positively gated high-avidity CTLs was reduced by 50%(down to 15.8% from 29.1%) when the mel526 cells were prein-
cubated with low-avidity G209n-specific CTL clones. The inhib-
itory effects of low-avidity CTLs at different ratios on CD107
expression by high-avidity CTLs are shown in Figure 6C. In all,
these data demonstrate that low-avidity CTLs can inhibit
degranulation of high-avidity CTLs against tumor cells.
DISCUSSION
It is increasingly recognized that antigen recognition by T cells is
not Boolean but depends on avidity and the availability of
cognate peptides on the target cell surface. Our results reveal
another level of complexity in T cell recognition by demonstrating
that low-avidity CTLs can inhibit target lysis by high-avidity CTLs
in an antigen-specific manner. The mechanism of inhibition in-
volves stripping of specific peptide-major histocompatibility
complexes (pMHCs) by low-avidity CTLs without cytolysis via
trogocytosis, thus transiently reducing the availability of cognate
pMHCs on the target cell surface for interaction with high-avidity
CTLs. As such, CTLs may constantly modulate the repertoire of
pMHCs on target cells, even in the absence of a cytolytic
response, via low-affinity TCR-pMHC interactions.
Competition for antigen and peptide MHCs is a known phe-
nomenon and is thought to shape the repertoire of cells respond-
ing to a limited amount of antigen (Kedl et al., 2000, 2002, 2003).
The outcome is the selection of lymphocytes with the highest af-
finity for antigen and suppression of lymphocytes with lower-af-
finity receptors. This occurs during the induction phase under
low antigen abundance. We previously demonstrated that anti-
gen-specific CTLs elicited via peptide vaccines in melanoma pa-
tients are predominantly low avidity and poor at tumor lysis, with
relatively few high-avidity CTLs that lysed tumor cells efficiently
(Stuge et al., 2004). This may seem paradoxical in light of the
prior studies of competition for antigen, but the key difference
is antigen availability. Current vaccine approaches generally
involve high antigen doses, which favor expansion of low-avidity
CTLs as these are more abundant than high-avidity specific
CTLs due to cross-reactivity. In contrast, competition for antigen
and selection of dominant high-avidity clones has been
observed only when antigen is at limited densities (Kedl et al.,
2000, 2002, 2003).
In this study, we demonstrated using fluorescent microscopy
that both high- and low-avidity CTLs can effectively capture
cognate peptide-MHCs from target cells via trogocytosis. We
further demonstrated that biotin/peptide-pulsed mel526 target
cells incubated with low-avidity G209n-specific CTL clones dis-
played less streptavidin-PE expression, confirming that the sur-
face density of G209n peptide-MHCs had been reduced by
interaction with low-avidity G209n-specific CTLs. Importantly,
low-avidity CTLs displayed similar capacity to undergo trogocy-
tosis as that of high-avidity CTLs but with little to no degranula-
tion or cytotoxicity. Low-avidity CTLs were fully competent to
lyse target cells presenting cognate peptide at higher concentra-
tions (Figure S1), confirming that these cells were functionally
cytolytic. We further investigated whether increasing the avail-
ability of cognate peptides on target cells reduced the inhibitory
effect by low-avidity CTLs. Indeed, increasing the concentration
of G209n peptide resulted in a reduction of the inhibitory effectCell Reports 8, 871–882, August 7, 2014 ª2014 The Authors 877
Figure 5. Level of Trogocytosis Is Dependent on Antigen Specificity and Peptide Concentration and Is Equal in Low- and High-Avidity
CTL Clones
(A) FACS analysis showing the percent of trogocytosis of both high- and low-avidity CTL clones specific for G209n at 1 ng/ml. Line graph shows increasing
concentrations of G209n peptide on APCs show greater levels of trogocytosis for either CTL group. FACS analysis showing the levels of trogocytosis when
incubating G209n-specific high- and low-avidity CTLs with PKH67-labeled mel526 melanoma cells.
(B) We used CMV-specific CTLs as a control for measuring G209-specific trogocytosis in both pulsed HmyA2GFP and mel526 cell line. The figure highlights
peptide specificity of trogocytosis and the inability of CMV-specific CTLs to undergo trogocytosis when incubated with mel526 cell line.by low-avidity CTLs (Figure S6), further confirming that the anti-
gen-specific inhibitory effect is dependent on peptide availability
on the target cell surface.878 Cell Reports 8, 871–882, August 7, 2014 ª2014 The AuthorsThe Jacobson and Lotem groups demonstrated that trogocy-
tosis could be used to detect and isolate antigen-specific CTLs
via either transfer of pMHCs (Tomaru et al., 2003), membrane
Figure 6. Suppression of Degranulation by Low-Avidity CTL
(A) FACS analysis showing expression of CD107A on trogocytosis-positive populations of both low-avidity CTLs and high-avidity CTLs following incubation with
G209n-peptide-pulsed HmyA2GFP cells.
(B) FACS analysis showing differences in CD107A expression in trogocytosis-positive populations of high-avidity CTLs and low-avidity CTLs and impact of
low-avidity CTLs followed by addition of high-avidity CTLs when incubated with mel526 cell line labeled with PKH67. To measure the expression of CD107A on
high-avidity CTLs following incubation with low-avidity CTLs, each CTL population was separately stained with differently conjugated CD8 antibody (Pacific Blue
for high avidity and Ds Red for low avidity) and gated on only Pacific-Blue-positive high-avidity CTLs.
(C) Overall percentage of CD107 expression selectively in high-avidity effectors mixed with that of low-avidity CTL clones (high versus low, p% 0.028; high versus
high + low [1:1], p% 0.05; high versus high + low [1:2], p% 0.035; high versus high + low [1:4], p% 0.034). Assays were performed in triplicate. Bars reflect SD
between assays in three separate experiments.(Machlenkin et al., 2008), or surface antigens (Eisenberg et al.,
2013). Using trogocytosis and signaling analysis, the Lotem
group also demonstrated that a peptide-specific (MART26–
MART35) tumor-infiltrating lymphocyte response consisted of
individual T cells with different functional responses (Uzana
et al., 2012), consistent with our previous findings that only
high-avidity TAA-specific T cells could kill tumor cells (Stugeet al., 2004). An important distinction between the work
presented here and these prior publications is our focus on the
interplay between T cells of different avidities for the same anti-
gen and between T cells specific for different antigens (MART
and gp100). Our use of HLA-A2-GFP transfer from target to
T cells to measure trogocytosis provided a very sensitive and
specific readout, allowing us to detect trogocytosis down toCell Reports 8, 871–882, August 7, 2014 ª2014 The Authors 879
the picogram level of specific peptides. This allowed us to
demonstrate that T cells have different peptide thresholds for
trogocytosis versus cytotoxicity (Figure S6). Differences in
downstream signaling properties of high- and low-avidity CTLs
that underlie their different functional responses are currently
under investigation.
These findings have clinical implications. The inhibitory effect
of low-avidity CTLs on high-avidity CTL tumor lysis could at least
in part explain the poor clinical responses observed in many
cancer peptide vaccine trials (Rosenberg et al., 2004). As such,
vaccines targeting T cell responses need to take into account
avidity. This applies not only to cancer vaccines but also vac-
cines for infectious diseases. These findings also have implica-
tions in self-tolerance. It is well established that low-avidity
CTLs specific for self-peptides exist in the mature T cell reper-
toire (Bouneaud et al., 2000; de Visser et al., 2000; Redmond
and Sherman, 2005). These cells could inhibit occasional high-
avidity CTLs specific for self-antigens that may escape negative
selection. As such, antigen-specific inhibition of high-avidity CTL
by low-avidity CTL represents a form of immune regulation.EXPERIMENTAL PROCEDURES
Cells
HLA-A*0201-restricted clonal G209n-specific (gp100: 209–217 [ITDQVPFSV])
and M27- specific (MART: 26–35 [ELAGIGILTV]) CD8-positive T cells lines are
listed in Table 1 and have been characterized previously (Stuge et al., 2004).
CMV-specific (CMVpp65: 495-503 [NLVPMVATV]) and FLU-specific (influenza
A virus M1: 58–66 [GILGFVFTL]) CTL clones were generated from healthy
donor peripheral blood mononuclear cells as previously described (Stuge
et al., 2004). All clones were maintained by biweekly stimulation with anti-
CD3 and irradiated feeder cells. Cells were used in assays between day 15
and 21 following stimulation. Melanoma cells and T2 cells were maintained
in cell culture medium (Iscove’s modified Dulbecco’s medium and 10% fetal
bovine serum [FBS]) whereas CTL clones were maintained in ‘‘CTL medium’’
(cell culture medium supplemented with 2% human AB serum). The HLA-
A*0201-positive melanoma line (mel526) was obtained from the Surgery
Branch of the National Cancer Institute. The HLA-A*0201-positive melanoma
line (MeWo) and the T2 cell line were purchased from American Type Culture
Collection (ATCC) and maintained according to instructions provided by
ATCC. Mel526 and MeWo express both MART and gp100 as confirmed by
immunohistochemical staining. Cells were trypsinized using trypsin/EDTA
solution (Gibco) before use. T2 cells are HLA-A*0201-positive and were pulsed
prior to assays with peptides indicated in the text below. The immortalized B
cell line expressing HLA-A*201 coupled to GFP (HmyA2GFP cells) was ob-
tained from NIH (generous gift of Dr. Steven Jacobson; Tomaru et al., 2003).
To generate HmyA2GFP cells, the HLA-A and B locus defective B cell line
(Hmy2.CIR) was transfected with the RSV-HLA-A2 vector containing GFP
expression.
Cytotoxic Assays
Cytotoxic assays were performed using the 51-chromium (51Cr)-release assay
as described previously (Stuge et al., 2004). Briefly, mel526, MeWo, or T2 cells
were labeled overnight with 51Cr and then washed and suspended to 105 cells/
ml. One hundred microliters of target cells were incubated with 100 ml CTL
clones at various effector-to-target (E:T) ratios in round-bottom 96-well tissue
culture plates and centrifuged 200 3 g for 1 min to bring together the cells at
the bottom of the plate and initiate the assay. Following a 4 hr incubation at
37C and 7.0% CO2, cells were resuspended with a multichannel pipette,
centrifuged 550 3 g for 5 min. Forty microliters of cell-free supernatant was
transferred from each well to 60 ml scintillation fluid, mixed well, and counts
per minute (cpm) were determined by scintillation counting. Percent specific
release (PSR) of 51Cr from target cells was calculated by the formula 100 3880 Cell Reports 8, 871–882, August 7, 2014 ª2014 The Authors(cpm [experimental]  cpm [minimum release])/(cpm [maximum release] 
cpm [minimum release]). Maximum release wells received 100 ml 2% Nonidet
P-40 (Sigma) instead of CTLs to lyse all target cells. Minimum release wells
received 100 ml CTL medium instead of CTLs. Inhibition of tumor lysis by
low-avidity CTL was assessed as follows unless indicated otherwise: 100
microliters of 51Cr-labeled target cells was incubated with 50 ml low-avidity
TAA-specific CTL clones, or viral antigen-specific CTL clones, at various E:T
ratios for 1 or 1.5 hr. PSR of 51chromium from target cells was calculated
from 40 ml cell-free supernatants as described above. Percent inhibition was
calculated by the formula 100 3 (PSR[high avidity + target]  PSR[low +
high avidity + target])/PSR(high avidity + target). All assays were performed
in triplicate.
Tetramer Decay Assay to Elucidate Differences in T Cell Avidity
The rate of dissociation of bound pMHC tetramers from antigen-specific
T cells upon addition of a competing antibody or Fab fragment may be used
as a relativemeasure of the difference in TCR affinities between T cells (Savage
et al., 1999). The method we employed utilized iTag MHC class I human
tetramer – streptavidin (SA)-PE (MBL International). Tetramer at 5 mg/ml and
1:200 dilution of fluorescein isothiocyanate (FITC) primary conjugated anti-
CD8 (clone 3B5; BD Biosciences) was incubated with 0.5 3 106 low- and
high-avidity cells individually at room temperature for 30 min. Cells were
washed three times with ice cold PBS and kept at 4C for the duration of the
assay. Fab fragment of blocking antibody, HLA-A2 antibody (GeneTex), was
generated by using Pierce Fab Micro Preparation Kit (Thermo Scientific). To
the tetramer/CD8-stained high- and low-avidity CTLs, 20 mM of Fab fragment
HLA-A2 was added to block tetramers from rebinding once dissociated. Con-
trol cells were stained with tetramer and CD8 but without HLA-A2 Fab frag-
ment blocking. Aliquots of the high and low populations were collected and
resuspended in 2% paraformaldehyde at time points 0, 10, 20, 30, 50, and
75 min. Samples were analyzed by fluorescence-activated cell sorting
(FACS) FlowJo software (Treestar) to determine decay of fluorescent intensity
of tetramer-positive cells gated CD8 population over time. Analysis was per-
formed on data collected from three separate experiments. Data were fitted
using a linear mixed effects model to test intercept and slope over time by
group effects. Calculations were based on the nlme package in R version
2.12.1.
Peptides and Peptide Pulsing
T2 cells, mel526, or HmyA2GFP cells were pulsed with the HLA-A*02:01-bind-
ing gp100(209–217) (ITDQVPFSV) peptide or an extended variant connected
to a flexible 17-amino-acid linker peptide with a biotinylated C terminus:
ITDQVPFSV-GGGSGGGSGGGSGGGSK-biotin (G209n-linker-biotin). Cells
were pulsed 1 hr with indicated peptide concentrations at 37C in 7.0% CO2
in 3 ml culture medium. Pulsed cells were washed three times with 10 ml
RPMI-1640 with 5% normal calf serum (NCS) and suspended in CTL medium.
Tomonitor modulation of antigenic peptide on target cell surfaces, 105 T2 cells
pulsed with 10 mM biotinylated G209n-linker-biotin were incubated with or
without 106 low-avidity G209n-specific or FLU-specific CTL clones in 200 ml
CTL medium in a 96-well round-bottom tissue culture plate containing 1.0 ml
anti-CD107a and 0.5 ml anti-CD107b monoclonal antibodies (mAbs) conju-
gated with allophycocyanin (to simultaneously monitor degranulation by
CTL) at 37C in 7.0% CO2. After 90 min, cells were transferred to 5 ml FACS
tubes (Becton Dickinson). Cells were then washed and suspended in 100 ml
CTL medium with 1:100 dilutions of FITC-conjugated anti-human CD8 and
streptavidin-PE (Caltag) and incubated 30 min on ice. Cells were washed,
resuspended in PBS 5% NCS, and analyzed by flow cytometry.
Measurement of Calcium Flux
High- and low-avidity G209n-peptide-specific CTLs were suspended in 1ml of
RPMI 1640 media (Life Technologies) supplemented with 10% FBS and 1%
PenStrep (Life Technologies) to a final count of 1.0 3 106 cells/ml, and cells
were centrifuged and resuspended in 1 ml of 13 PBS in a 1.7 ml centrifuge
tube. A Rhod-3AM cell permanent fluorescent calcium indicator kit (Life Tech-
nologies) was used to determine small changes in intracellular calcium con-
centrations in stimulated low- and high-avidity CTLs by FACS analysis. CTLs
were loaded with a final concentration of 0.75 mM Rhod-3AM along with
1:250 dilution of allophycocyanin-conjugated anti-human CD8a antibody
HIT8a clone (Biolegend) to isolate CD8-positive CTLs. Cells were incubated
at 37C for 45 min in the dark, pelleted, and then washed two times with 13
PBS to remove residual Rhod-3AM stain. Cells were stimulated with
HmyA2GFP APCs and were previously pulsed with (G209n) peptide at a con-
centration of 100 pg/ml. APCs were coated on round-bottom 96-well plates
prior to addition of CTLs. Plate was flash spun for 30 s to encourage cell-cell
interactions and timer of stimulation was started. Stimulation was performed
at a ratio of one APC for every three CTLs. After 7 min of stimulation, cells
were transferred to a FACS tube and run on FACSCalibur (BD Biosciences)
for FACS analysis. Cells were gated to isolate for CD8-positive CTLs, and
GFP expression on CD8-positive cells was utilized as a positive indicator of
acquisition of MHC-peptide complexes via trogocytosis. CD8 CTLs were
analyzed for differences in calcium fluorescence between trogocytosis (GFP)
positive and negative CTLs.
Fluorescent Cell Membrane Labeling
To achieve a GFP-like expressing cellular membrane onmel526 cells for imag-
ing and FACS analysis purposes, a PKH67 fluorescent cell linker dye kit
(Sigma-Aldrich) was utilized. mel526 cells were resuspended in 13 PBS at a
final count of 1.0–2.0 3 106 cells/ml. Cells were spun down at 1,000 rpm for
5 min, and all supernatant was removed and cells resuspended in 500 ml
Diluent C. In a separate 1.7 ml centrifuge tube, PKH67 dye was prepared to
a working concentration of 1 mM in 500 ml of Diluent C. The 1 mM PKH67 dye
was mixed with 500 ml cell suspension into a 2 ml centrifuge tube resulting in
0.5 mM PKH67 dye final concentration. Cells were allowed to incubate for
5 min at 37C in the dark. Cells were washed with 800 ml FBS to stop staining
reaction, spun to a pellet at 1,000 rpm for 10 min, and subsequently washed
with 2 ml 13 PBS two times to remove excess stain. Cells were resuspended
in 1 ml of 13 PBS and ready for use and analysis.
Live-Cell Imaging
Live-cell analysis was performed to visualize the exchange of membrane
proteins via trogocytosis in interactions between CD8+ low- and high-avidity
G209n-specific CTLs and GFP expressing HmyA2GFP APCs pulsed with
G209n peptide. To perform these experiments, we utilized a Zeiss Axio
Observer Z1 Inverted Microscope coupled to an Exfo Xcite fluorescence illu-
mination apparatus capable of detecting DAPI, eGFP, DS Red, and Far Red
emission spectra. Images were captured via a Hamamatsu EMCCD C9100-
13 Monochrome Camera and Zeiss MRc5 Digital Color Camera. A 633/1.3
numerical aperture Plan-NeoFluar Multi Immersion objective was coupled
with Optovar 1.63 magnification resulting in 1003 final magnification. Live-
cell imaging was aided by a Pecon/Zeiss incubation system with heated stage
insert and enclosure with 5%CO2 control. Cells were placed on 35mmpoly-d-
lysine-coated glass-bottom dishes (MatTek; P35GC-1.5-10-C). All analysis
was performed using Zeiss AxioVision software version 4.8 for Microsoft
Windows.
Generation of Tumor Aggregates
To generate a mel526 tumor/CTL aggregate, approximately 2 3 105 mel526
plus 1 3 105 high- or low-avidity CTLs mel526 were mixed together in PBS
(Mediatech) and spun into an aggregate pellet in a microcentrifuge tube.
Following removal of the supernatant, the aggregate was drawn into a micro-
pipette tip (no more than 10 ml in volume) and released onto the surface of a
nucleopore filter membrane (0.8 mm pores; Millipore) floating on gelfoam
(Pharmacia &Upjohn) in D10medium. The tumor/CTL aggregate was then har-
vested after 48 hr in culture for analysis of apoptosis.
Quantification of Viable Mel526 Cells in Tumor/CTL Aggregate
In attempts to identify the cytolytic consequences of high-avidity CTLs versus
low-avidity CTLs in our mel526 tumor aggregate model, we adopted a viable
cell-counting methodology. The aggregate pellet described above was
formalin fixed and paraffin embedded and sliced to 3 mm and placed on glass
slides for imaging purposes. The segments then underwent immunohisto-
chemical staining for melan A (DAB: brown), caspase 3 (fast red), and hema-
toxylin (blue). Images of slide segments were taken at 203 magnification,
and identical large regions of interest of the aggregate were cropped at a fixeddimension for all slide images. Images were analyzed with Image Pro Premier
9.0 for Windows utilizing an automated cell-counting feature. A selection of
intact cells within the region of interest was manually selected to establish
criteria for nonlysed cells. The software then identified counts of the cells
that met the criteria within the fixed dimension region of interest for each
tumor/CTL aggregate slide. Quantification of viable nonlysed cells were
collected for six regions of interest for each mel526 aggregate with either
high-avidity CTLs, low-avidity CTLs, or a combination of low- and high-avidity
CTLs. Statistical analysis was performed using an unpaired t test of groups’
counts with significance assigned with p < 0.05.
In Vivo Experiments
C57BL/6J x C57BL/10SgSnAi)-[KO]gc-[KO]Rag2 mice were purchased from
Taconic Farms.
For in vivo assessment of tumor growth in the presence of T cell clones, mice
were injected subcutaneously in the left flank with 1.0 3 106 mel526 cells in
50 ml PBS. To facilitate injections and measurements, the fur was shaved
from left flank before injection of tumor cells and before determination of
subcutaneous tumor size. One day after tumor cell injection, the mice were
injected intravenously or retro-orbitally with 5.0 3 106 gp100-specific high-
avidity CTL (in 50 ml PBS; tu hi), gp100-specific high avidity CTL combined
with 3.0 3 107 gp100-specific low-avidity CTL (in 100 ml PBS; tu hi lo), or
gp100-specific high-avidity CTL combined with 3.0 3 107 flu-specific CTL
(tu hi flu). After 40 days, tumor volume was estimated in each mouse: subcu-
taneous tumor length (longest diameter) and width was estimated externally
using a caliper and the volume was calculated by the formula tumor volume =
1∕2(length 3 width2). All mice were euthanized after tumor volume measure-
ment on day 40. All mice were kept in separate pathogen-free facilities, and
all protocols were approved by the Stanford University Institutional Animal
Care and Use Committee.
CD107 Mobilization Assay
High- and low-avidity CTL, mel526 (pulsed or nonpulsed), peptide-pulsed T2,
or HmyA2GFP (pulsed or nonpulsed) cells were combined as described in
figure legends for the individual experiments. Assays were performed as
described previously (Rubio et al., 2003). Briefly, the following was added in
order to each well: 1 ml of 2 mM monensin (Sigma) in 100% EtOH, 100 ml of
target cells, 100 ml of effector cells, and 1 ml anti-CD107a and 0.5 ml anti-
CD107bmAbs conjugated to allophycocyanin. For the inhibition assays, target
cells were preincubated with 50 ml low-avidity CTL for 1.5 hr prior to adding
50 ml high-avidity CTL. E:T ratios were as indicated for the individual experi-
ments. The cells were mixed using a multichannel pipette at each addition of
cells. The plate was centrifuged at 200g for 1 min to pellet cells and then incu-
bated at 37C and 7.0% CO2 for the indicated time periods. After the incuba-
tions, the plates were centrifuged to 500 g to pellet cells and the supernatant
was removed. Cell-cell conjugates were disrupted by washing the cells with
PBS supplemented with 0.02% azide and 0.5 mM EDTA, mixed vigorously,
and then stained with PE-conjugated anti-human CD8 antibodies (Caltag
Laboratories) and analyzed by flow cytometry using a two-laser, four-color
FACSCalibur. CTLs were identified by forward- and side-scatter signals and
then selected for CD8-positive cells.
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